Skip to main content

Synergus

  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Contact Us
    • Subscribe to Synergus RWE News
    • IGES group
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Hands-on market access support
      • Reimbursement dossier / HTA dossier
      • Reimbursement/DRG analysis
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog

You are here

Home ยป Blog
  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Subscribe to Synergus RWE News
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Reimbursement/DRG analysis
      • Reimbursement dossier / HTA dossier
      • Hands-on market access support
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog
Use of generic quality of life measures in reports from NICE
11 Apr 2016

We are evolving the insight in the data we have in our HTA update search platform. In this analysis we looked at the occurrence of the two major quality of life measures, EQ-5D and SF-36, in reports from NICE in the United Kingdom. Learn more about our service here:

  • HTA Update Search
  • Patient reported outcomes

 

Tags: 

  • Quality of Life
  • United Kingdom
  • SF-36
  • EQ-5D
  • HTA
  • LinkedIn
  • Twitter

Contact us

Tags

Alzheimer
Artificial Intelligence
Breast cancer
China
Co-payment
Corona virus
Country specific
Coverage with Evidence Development
COVID-19
Data Science in Oncology
Dementia
Denmark
DHS Belgium
DHS France
DHS Germany
Diabetes
Digital Health
Digital Heath Strategies
Disease Specific
EMA
Empowered Patients
EQ-5D
EU HTAR
EU HTAR IVD
EU HTAR Medtech
Finland
France
Funding
Germany
Health Economics
Heart Failure
HQRWE_Fracture
HQ_RWD
HTA
Imaging
Innovation Funding
Italy
IVD
Legislation
Lung Cancer
Market Access
Medical Device
Melanoma
Mental Health
Multiple Sclerosis
Myeloma
Netherlands
Norway
Obesity
Oncology
Out-patient procedures
Patient Registries
Pharma
Quality of Life
R-RCT
Real World Data
Real World Evidence
RefugeeMD
Registries
Rheumatoid Arthritis
RWD Scientific Impact
SF-36
Stroke
Sweden
The Netherlands
Throat Cancer
Transferability of Outcomes
United Kingdom
Value Based Healthcare
  • Home
  • About
  • RWE impact
  • Market Access
  • HEOR
  • Events/Webinars
  • News
  • Blog